Therapy of chronic hepatitis C with simeprevir
Petr Urbánek Orcid.org 1
+ Affiliation
Summary
This review presents all essential information on simeprevir and its use in the therapy of chronic hepatitis C. The review is focused on the curent role of simeprevir in IFN‑based regimens as well as its role in IFN‑free regimens.
Keywords
pegylated interferon, simeprevir
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment‑naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‑1): a phase 3, randomised, double‑blind, placebo‑controlled trial. Lancet 2014; 384(9941): 403–413. doi: 10.1016/S0140‑6736(14)60494‑3.
2. Manns M, Marcellin P, Poordad F et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment‑naive patients with chronic hepatitis C virus genotype 1 infection (QUEST‑2): a randomised, double‑blind, placebo‑controlled phase 3 trial. Lancet 2014; 384(9941): 414–426. doi: 10.1016/S0140‑6736(14)60538‑9.
3. Forns X, Lawitz E, Zeuzem S et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146(7): 1669–1679. doi: 10.1053/j.gastro.2014.02.
051.
4. Scott J, Gilles L, Fu M et al. Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‑1, QUEST‑2 and PROMISE studies. J Viral Hepat 2014. doi: 10.1111/jvh.12365.
5. Urbánek P, Husa P, Šperl J et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Gastroent Hepatol 2014; 68(6): 499–512.